# A Study of Anti-PD-1 and LAG-3 Bispecific Antibody(AK129) Combined With Chemotherapy With or Without Cadonilimab in the First-line Treatment of Unresectable Locally Advanced or Metastatic G/ GEJ Adenocarcinoma

> **NCT06586294** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Akeso** · enrollment: 294 (estimated)

## Conditions studied

- Gastric Adenocarcinoma
- Gastroesophageal Junction Adenocarcinoma

## Interventions

- **DRUG:** Drug: AK129 Drug：oxaliplatin Drug：capecitabine
- **DRUG:** Drug: AK129 Drug：cadonilimab Drug：oxaliplatin Drug：capecitabine

## Key facts

- **NCT ID:** NCT06586294
- **Lead sponsor:** Akeso
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-09-10
- **Primary completion:** 2026-07
- **Final completion:** 2026-07
- **Target enrollment:** 294 (ESTIMATED)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06586294

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06586294, "A Study of Anti-PD-1 and LAG-3 Bispecific Antibody(AK129) Combined With Chemotherapy With or Without Cadonilimab in the First-line Treatment of Unresectable Locally Advanced or Metastatic G/ GEJ Adenocarcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06586294. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*